Riboxin bufus Renewal solution 2% 5ml ampoules, 10pcs

Composition

>

1 ml of the solution contains:

Active ingredient:

inosine (riboxin) – 20 mg

excipients:

methenamine (hexamethylenetetramine) – 2 mg

sodium hydroxide

(1 M sodium hydroxide solution) – up to pH 7.8-8.6

water for injection-up to 1 ml

Pharmacological action

Riboxin is a derivative (nucleoside) of purine, a precursor of adenosine triphosphate (ATP). It belongs to the group of drugs that stimulate metabolic processes. It has antihypoxic and antiarrhythmic effects. Increases the energy balance of the myocardium, improves coronary blood circulation, and prevents the consequences of intraoperative renal ischemia. It is directly involved in glucose metabolism and contributes to the activation of metabolism under conditions of hypoxia and in the absence of ATP.

Activates the metabolism of pyruvic acid, which is necessary to ensure the normal process of tissue respiration, and also promotes the activation of xanthine dehydrogenase. It stimulates the synthesis of nucleotides, increases the activity of certain enzymes of the Krebs cycle.

Penetrating into the cells, it has a positive effect on the processes of metabolism in the myocardium-it increases the strength of heart contractions and promotes more complete relaxation of the myocardium in diastole, resulting in an increase in stroke volume. The mechanism of antiarrhythmic action is not fully understood.

Reduces platelet aggregation, activates tissue regeneration (especially the myocardium and gastrointestinal mucosa).

Pharmacokinetics

It is metabolized in the liver with the formation of glucuronic acid and its subsequent oxidation. A small amount is excreted in the urine.

Indications

Complex treatment of myocardial infarction, coronary heart disease, heart rhythm disorders caused by the use of cardiac glycosides, against the background of myocardial dystrophy after infectious diseases.

Liver diseases (hepatitis, cirrhosis, fatty degeneration), urocopromorphyria.

Operations on an isolated kidney (as a means of pharmacological protection when blood circulation is turned off).

Contraindications

Hypersensitivity to the drug, gout, hyperuricemia, pregnancy, lactation, age up to 18 years (efficacy and safety have not been established). Use with caution in patients with renal insufficiency.

Side effects

Allergic reactions: pruritus, hyperemia of the skin, urticaria (the drug should be discontinued).

Rarely: increased uric acid concentration in the blood, exacerbation of gout (with prolonged use).

Interaction

Currently not identified.

How to take, course of use and dosage

The drug is used intravenously in a slow jet or drip (40-60 drops per 1 minute). Treatment begins with the introduction of 200 mg (10 ml of 2% solution) 1 time a day, then, if well tolerated, the dose is increased to 400 mg (20 ml of 2% solution) 1-2 times a day. The duration of treatment is 10-15 days.

Jet use of the drug is possible in acute cardiac arrhythmias in a single dose of 200-400 mg (10-20 ml of a 2% solution).

For pharmacological protection of ischemic kidneys, riboxin is administered intravenously in a single dose of 1200 mg (60 ml of 2% solution) 5-15 minutes before clamping the renal artery, and then another 800 mg (40 ml of 2% solution) immediately after restoring blood circulation.

When administered dropwise into a vein, a 2% solution of the drug is diluted in a 5% dextrose (glucose) solution or an isotonic sodium chloride solution (up to 250 ml).

Form of production

Solution for intravenous use

Storage conditions

In a dark place, at a temperature of 15-25 °C.

Shelf life

3 years

Active ingredient

Inosine

Conditions of release from pharmacies

By prescription

Dosage form

solution for infusions

Description

For adults as directed by your doctor

Indications

Angina, Cirrhosis, Arrhythmia, Hepatitis, Myocardial Infarction